Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting.
about
A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.The Essentials of a Global Index for Cognitive Function.Guidelines versus individualized care for the management of CINV.Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-concluding thoughts.
P2860
Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Choice of study endpoint signi ...... y-induced nausea and vomiting.
@en
type
label
Choice of study endpoint signi ...... y-induced nausea and vomiting.
@en
prefLabel
Choice of study endpoint signi ...... y-induced nausea and vomiting.
@en
P2093
P2860
P1476
Choice of study endpoint signi ...... y-induced nausea and vomiting.
@en
P2093
George Dranitsaris
Lisa Vandermeer
Mark Clemons
Stephanie Smith
P2860
P2888
P304
P356
10.1007/S10549-015-3669-8
P407
P577
2016-01-05T00:00:00Z
P5875
P6179
1045998509